SURAKSHA Suraksha Diagnostic Q1 FY27 results (Apr–Jun 2026) and concall
Management summary
- Suraksha Diagnostic Limited reported a strong Q1 FY27, with robust revenue growth of 21% and significant PAT growth of 40%.
- Margin expansion was noted across both mature and newer centers, with the latter turning profitable.
- The genomics segment showed exceptional growth, and the company continued its network expansion strategy into new geographies while focusing on operational efficiencies.
Source: Inve concall analysis and management guidance record.
Highlights
-
Revenue of INR 887 million, up 21% YoY, reflecting strong business momentum.
-
EBITDA margin expanded 200 bps to 36%, driven by volume expansion and operating leverage.
-
PAT grew significantly by 40% YoY to INR 128 million, demonstrating improved profitability.
-
Genomics business showed robust growth of 136% YoY, reaching INR 13.7 million, with positive outlook for future.
What they filed
Q1 FY27: revenue up 20.0%, net profit up 30.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 59 | 64 | 70 | 76 | 76 +29% | 79 +23% | 84 +20% |
| EBITDA | 18 | 20 | 24 | 24 | 23 +28% | 24 +20% | 29 +21% |
| Net profit | 6 | 8 | 10 | 9 | 8 +33% | 7 −12% | 13 +30% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Profitability
Overall EBITDA Margin Profitability · FY27 · High confidence not below 34%
EBITDA Margin Profitability · FY28-FY29 · Medium confidence more than current
Previously 33%-34% → more than current
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Margin expansion drivers Direct
The margin expansion is, of course, because of the volume expansion. As the revenues scale up and our major fixed costs remain the same, there is operating leverage and the margin expands.
Clarifies the primary driver behind the 400 bps margin expansion, indicating operating leverage from increased volumes.
Asked by Om
Genomics business growth trajectory Direct
So, we are quite positive about the incremental growth that is coming from the genomics business. The adoption has been really good in the medical fraternity and people are becoming more and more aware about all the products and services that we are offering as of now in the mark
Provides management's optimistic outlook on the genomics segment, citing increasing awareness and adoption as key drivers.
Asked by Om
Unlock risks & concerns, Q2 FY27 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 3 risks, concerns & management red flags
- 4 watchlist triggers for Q2 FY27
- +8 more guidance targets & verbatim management quotes
- +5 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





